Parasitemia

Parasitemia refers to the presence of parasites in the blood. It is a fundamental indicator in the study and management of parasitic infections, which affect millions globally, particularly in tropical and subtropical regions. The level of parasitemia, or the number of parasites detectable in a given volume of blood, can fluctuate throughout the course of an infection and is influenced by various factors, including the host’s immune status and the parasite’s life cycle.

Biological Basis

The biological basis of parasitemia involves the active replication and circulation of parasitic organisms or their genetic material within the host’s bloodstream. For diseases like Chagas disease, caused by the parasiteTrypanosoma cruzi, the presence of parasite DNA in the blood, often detected using sensitive molecular techniques such as Polymerase Chain Reaction (PCR), directly indicates an active infection. Research has shown that the detection ofTrypanosoma cruziDNA by PCR assays in seropositive blood donors can correlate with antibody levels and may indicate the resolution of infection over time.^[1]Host genetic factors can influence an individual’s susceptibility to and levels of parasitemia. For instance, specific single nucleotide polymorphisms (SNPs) have been identified that are associated with parasitemia as measured by PCR.^[2]

Clinical Relevance

The of parasitemia holds significant clinical relevance for diagnosis, prognosis, and treatment monitoring. It serves as a crucial diagnostic tool, especially in the acute phase of parasitic infections, to confirm the presence of the pathogen. In chronic conditions, like Chagas disease, parasitemia by PCR is an important phenotype studied in genome-wide association studies (GWAS) to uncover genetic factors contributing to disease progression.^[2]Furthermore, the level of parasitemia can act as a prognostic marker, influencing the risk of developing severe disease manifestations. Studies have indicated that parasitemia detected by PCR can influence the risk of progression to chronic Chagas cardiomyopathy.^[3]Monitoring parasitemia is also essential for assessing the efficacy of antiparasitic drug treatments, with a reduction or clearance of parasites from the blood signaling a positive therapeutic response.

Social Importance

From a societal perspective, understanding and accurately detecting parasitemia is vital for public health and disease control efforts. Effective detection methods enable early intervention, which can prevent disease transmission within communities and reduce the overall burden of parasitic diseases. Globally, insights into the genetic underpinnings of parasitemia can lead to the development of improved diagnostic tests, more effective therapies, and targeted public health strategies. For example, identifying genetic variants, such as a cluster of SNPs within introns of theCOL14A1 gene, associated with PCR positivity can shed light on host-parasite interactions and potential new targets for therapeutic or preventive measures.^[2] This knowledge contributes significantly to mitigating the impact of widespread parasitic infections on human health and socioeconomic development.

Limitations in Statistical Power and Replication

The modest sample size of the cohort, comprising 580 subjects, represents a significant limitation in achieving robust genome-wide significant associations for parasitemia and other Chagas-related traits. Despite being the largest GWAS of Chagas cardiomyopathy at the time, this sample size likely contributed to the “limited number of significant SNP variants” identified, with many associations reported at suggestive p-values (e.g., <10-6) rather than the stringent genome-wide significance threshold.^[2] This suggests that the detected effect sizes might be inflated or represent false positives, underscoring the need for further validation. Consequently, the research explicitly calls for “expanded cohorts and meta-analyses, and targeted studies of candidate genes” to confirm and extend these preliminary findings, highlighting the current replication gap for the identified genetic signals.^[2]

Challenges in Population Ancestry and Generalizability

The study cohort, drawn from the Brazilian population, exhibits a high degree of genetic diversity and admixture, with significant proportions of African, European, and Native American ancestries.^[2] While the study meticulously adjusted for population stratification using multidimensional scaling, the complex ancestral background can complicate the direct transferability of findings to populations with different genetic compositions.^[4] Furthermore, the research observed a discrepancy between self-reported race and genetic ancestry, where individuals self-identifying as white or black often displayed broad multi-racial admixture.^[2] This highlights the challenge of using self-reported ancestry in admixed populations and its potential impact on interpreting genetic associations. Additionally, the cohort’s composition of T. cruziseropositive individuals (blood donors and cardiomyopathy patients) limits the ability to investigate genetic factors predisposing toT. cruziinfection itself, as exposed seronegative controls were not included.^[2]

Phenotypic Specificity and Unaccounted Variables

The assessment of parasitemia was conducted using PCR, a sensitive method for detectingT. cruzi DNA.^[2]However, the research does not elaborate on specific methodological considerations that might influence the of parasitemia, such as the intermittent nature of parasite detection in chronic Chagas disease, potential fluctuations in parasite load over time, or the precise sensitivity and specificity of the PCR assay used.^[1]These factors could introduce variability in the parasitemia phenotype, potentially leading to misclassification and weakening the power to detect genetic associations. Moreover, the study primarily focused on host genetic factors, acknowledging that complex diseases like Chagas cardiomyopathy and the dynamics of parasitemia are likely influenced by a multitude of environmental factors and gene-environment interactions. The absence of a comprehensive assessment of these non-genetic variables means that their confounding effects on parasitemia levels and disease progression, as well as their potential contribution to the “missing heritability” of these traits, remain largely unaddressed.

Variants

Genetic variations play a crucial role in an individual’s susceptibility and response to parasitic infections, including those caused by Trypanosoma cruzi, the causative agent of Chagas disease. Several single nucleotide polymorphisms (SNPs) and their associated genes have been identified that may influence the host’s ability to manage parasitemia, which is the level of parasites in the blood. These genetic factors can impact various biological pathways, from structural integrity to immune signaling, thereby affecting disease progression.

One such gene is COL14A1 (collagen, type XIV, alpha 1), a fibril-associated collagen that interacts with the fibril surface and plays a role in regulating fibrillogenesis, the process of forming collagen fibers. A cluster of 12 SNPs located within the introns of COL14A1, including rs10955961 , has been associated with PCR positivity for Trypanosoma cruziDNA, indicating a link to parasitemia levels.^[2] This suggests that variations in COL14A1 could influence the host’s capacity to control parasite burden, potentially by affecting tissue structure or the immune response within infected tissues. Furthermore, previous research has linked SNPs in COL14A1 to HIV-1 viral load, highlighting a broader involvement of this gene in the host’s response to chronic viral infections.^[2] Other variants also contribute to the complex genetic landscape of host-parasite interactions. The variant rs116303449 is situated in the 5’ untranslated region (UTR) of the ZNF396 gene, which encodes a zinc finger protein.^[2]Zinc finger proteins are well-known for their roles in binding DNA, RNA, and proteins, often acting as transcriptional regulators, meaning this variant could alter the expression of genes critical for immune function or cellular stress responses during infection. Similarly,rs57302454 is an upstream variant of TNFRSF10B-AS1 (also referred to as LOC254896), a long non-coding RNA that can influence the activity of TNFRSF10B, a gene encoding a death receptor involved in programmed cell death (apoptosis).^[2] Such a variant might modulate cell survival pathways or inflammatory processes that are vital in determining the outcome of parasitic diseases. Additionally, rs4408325 is associated with CCDC15-DT, a gene related to CCDC15, which produces a coiled-coil domain-containing protein.^[2] These proteins are frequently involved in protein-protein interactions and serve as structural components or signaling molecules, suggesting that variations in CCDC15-DT could impact cellular integrity or signal transduction pathways affected by T. cruziinfection. Their genomic locations within or near genes involved in fundamental cellular and immune processes imply a potential influence on how the host responds to parasitic challenge and manages parasite load.

Key Variants

RS ID	Gene	Related Traits
rs4408325	CCDC15-DT	parasitemia
rs10955961	COL14A1	parasitemia
rs116303449	ZNF396	parasitemia
rs57302454	TNFRSF10B-AS1	parasitemia
rs56279505	ADH1C - ADH7	parasitemia
rs1936166	LINC02540 - HTR1B	parasitemia
rs117559033	HS3ST4	parasitemia
rs10113221	CSMD1	parasitemia
rs196670	LCAL1 - DBIP1	parasitemia gut microbiome , breastfeeding duration
rs12483240	LINC00158 - MIR155HG	parasitemia

Defining Parasitemia in Chagas Disease

Parasitemia refers to the presence of parasites in the blood, a critical indicator in the context of Chagas disease, caused by the protozoan parasiteTrypanosoma cruzi (T. cruzi). Conceptually, it signifies active parasitic infection, ranging from acute phases with high parasitic loads to chronic stages where parasite detection can be intermittent or low. The detection ofT. cruziDNA in seropositive individuals serves as a precise operational definition for current or recent parasitemia, distinguishing ongoing infection from mere serological evidence of past exposure. Understanding parasitemia is fundamental to characterizing the disease state and its progression, particularly in chronic phases where its persistence is linked to pathological outcomes.^[3]

Diagnostic Approaches and Criteria

The primary diagnostic approach for detecting parasitemia in research and clinical settings involves molecular methods, specifically Polymerase Chain Reaction (PCR) assays. This method is highly sensitive and targets the detection ofTrypanosoma cruzi DNA, making “PCR positivity” a key diagnostic criterion and a direct measure of parasite presence in blood samples.^[1] While antibody levels, measured by systems like the Ortho T. cruziEIA test, indicate exposure and seropositivity, they do not directly quantify active parasitemia; rather, antibody levels may correlate with the detection ofT. cruzi DNA by sensitive PCR assays, suggesting a potential link between immune response and parasite load.^[1]

Clinical Significance and Disease Classification

The presence of parasitemia, particularly when detected by PCR, holds significant clinical relevance for classifying and understanding the progression of Chagas disease. Persistent parasitism, even at low levels, is implicated in the pathogenesis of chronic Chagas cardiomyopathy (CCC), the most severe manifestation of the disease, affecting 20-40% of patients in the chronic phase.^[5]Studies have indicated that parasitemia detected by PCR can influence the risk of progression to chronic Chagas cardiomyopathy, highlighting its role as a potential biomarker for disease severity and prognosis.^[3]Therefore, while Chagas disease classification often includes stages like acute, indeterminate, and chronic forms, the presence or absence of detectable parasitemia by PCR provides a crucial categorical dimension to this framework, informing clinical management and research criteria.^[1]

Clinical Evaluation and Imaging Assessment

The diagnosis of Trypanosoma cruziinfection and its progression, such as Chagas cardiomyopathy (CCC), relies on a comprehensive clinical evaluation combined with advanced imaging modalities. Initial assessment involves a detailed medical examination and health questionnaire to identify individuals at risk or presenting with symptoms. For instance, the indeterminate stage of chronic Chagas disease is characterized by seropositivity toT. cruzi without clinical evidence of cardiac or digestive forms, as determined by clinical examination, electrocardiogram (ECG), and X-ray studies.^[5] The presence of CCC is typically established by an expert panel of cardiologists who review clinical, laboratory, ECG, and echocardiogram (Echo) findings.^[1] Imaging techniques play a critical role in characterizing the extent of cardiac involvement. ECG measurements, including PR, QRS duration, and corrected QT intervals, are important parameters evaluated.^[2] Echocardiography provides crucial information on cardiac structure and function, such as ejection fraction (EF).^[2] An algorithm incorporating abnormalities in Echo or ECG measurements can trigger further review by experts, with this diagnostic approach demonstrating a sensitivity of 98% for detecting previously diagnosed CCC and a specificity of 95%.^[1]These tools help to identify the severe manifestations of Chagas disease, which can include heart failure, arrhythmia, and heart block.^[5]

Laboratory and Molecular Detection of Trypanosoma cruzi

Laboratory testing is fundamental for confirming Trypanosoma cruziinfection and assessing parasitemia. Serological assays, such as anti-T. cruzi antibody level measurements using systems like the Ortho T. cruzi EIA test, are widely employed to establish seropositivity.^[1]These antibody levels are important indicators of past or present infection. Molecular methods, particularly polymerase chain reaction (PCR), are utilized to detectT. cruziDNA, providing direct evidence of parasitemia.^[2] Sensitive PCR assays are capable of detecting Trypanosoma cruzi DNA, and studies have shown that antibody levels often correlate with the detection of T. cruzi DNA in seropositive individuals.^[1] The status of T. cruzi PCR is a key parameter in the characterization of infected subjects.^[2]While antibody tests confirm exposure, molecular tests like PCR directly assess the presence of the parasite, which is crucial for understanding disease activity and guiding treatment strategies, especially in chronic phases where persistent parasitism may drive inflammation.^[3]

Differential Diagnosis and Disease Progression

Distinguishing various forms of Chagas disease and differentiating it from other conditions is essential for accurate diagnosis and management. The indeterminate stage of chronic Chagas disease, defined by seropositivity toT. cruziwithout clinical signs of cardiac or digestive disease, requires careful differentiation from the more advanced clinical stages.^[5]The progression from this indeterminate stage to clinical chronic Chagas disease, such as cardiomyopathy or mega-syndromes, typically occurs over 10 to 20 years.^[1]Chronic Chagas cardiomyopathy (CCC) presents with severe manifestations like heart failure, arrhythmias, and thromboembolism, necessitating its distinction from other causes of dilated cardiomyopathy.^[5] The severity of CCC and its worse prognosis compared to other cardiomyopathies underscore the importance of accurate etiological diagnosis.^[5] Diagnostic challenges include the potential for misdiagnosis, which is mitigated by comprehensive evaluation including clinical expertise and standardized diagnostic criteria.^[1]

Biological Background

The presence of Trypanosoma cruziparasites in the bloodstream, known as parasitemia, is a fundamental aspect of Chagas disease, a condition caused by this protozoan parasite. Understanding the biological underpinnings of parasitemia is crucial for comprehending disease progression and the host’s response to infection. Chagas disease is a significant public health concern, particularly in Latin America, whereT. cruzi is naturally transmitted to humans through haematophagous reduviid bugs.^[2]

Trypanosoma cruzi Infection and Acute Phase

The journey of Trypanosoma cruziwithin a host begins with transmission, typically through the bite of an infected reduviid bug, leading to an initial acute phase of infection. During this phase, parasites actively replicate and circulate in the bloodstream, contributing to parasitemia. While many acute cases may be asymptomatic or present with mild symptoms, they frequently progress to a chronic indeterminate stage where individuals remain seropositive forT. cruziantibodies but show no overt clinical signs of cardiac or digestive disease.^[2]The sustained presence of the parasite, even at low levels, is a critical factor influencing the subsequent development of chronic disease manifestations.

Host Immune Response and Chronic Pathogenesis

The host’s immune system plays a dual role in controlling the parasite while also contributing to the pathogenesis of Chagas disease. Persistent parasitism, particularly within myocardial tissue, triggers a robust T cell-mediated inflammatory response.^[3]This chronic inflammation and the subsequent immune-mediated damage to heart tissue are central to the development of chronic Chagas cardiomyopathy (CCC), the most severe manifestation of the disease. Key biomolecules such as cytokines and chemokines are integral to this inflammatory cascade, orchestrating the recruitment and activation of immune cells.^[6] Furthermore, autoimmunity is believed to contribute significantly, where the immune system may target host cardiac cells and the conduction system, exacerbating tissue damage and disrupting normal cardiac homeostatic functions.^[7]

Genetic Influences on Infection and Disease Progression

Host genetic factors significantly modulate an individual’s susceptibility to T. cruziinfection and the progression of Chagas disease. Research indicates that a substantial portion of the variability in susceptibility to infection, as evidenced by the presence of antibodies, can be attributed to genetic predispositions.^[8]These genetic variations also influence the development of chronic Chagas cardiomyopathy and related electrocardiographic abnormalities.^[8] Studies focusing on candidate genes have highlighted the importance of innate and adaptive immune responses in CCC pathogenesis. For instance, heterozygosity for a specific variant in the MAL/TIRAP gene, which encodes an adaptor protein crucial for Toll-like receptor signaling, is associated with a lower risk of developing CCC.^[9] Similarly, polymorphisms in the TNFgene have been linked to reduced survival in patients with severe CCC, underscoring how genetic variations can impact immune regulatory networks and disease outcomes.^[10]

Systemic Consequences and Detection of Parasite Burden

The systemic impact of T. cruziinfection is profound, with chronic Chagas cardiomyopathy affecting 20-40% of chronically infected individuals, typically 10 to 20 years after the initial acute infection.^[2]This organ-specific pathology manifests as severe cardiac abnormalities including heart failure, arrhythmias, heart block, and thromboembolism, representing significant homeostatic disruptions and systemic consequences.^[2] The presence of T. cruziDNA, reflecting active infection or persistent parasite burden, can be reliably detected using sensitive PCR assays.^[1] Moreover, the levels of T. cruziantibodies in the bloodstream often correlate with the detection of parasite DNA, offering valuable insights into the infection status and potential resolution over time.^[1]Accurate assessment of parasitemia is therefore vital for monitoring disease progression and evaluating therapeutic interventions.

Prognostic Indicator in Chagas Disease

Parasitemia, particularly when detected by sensitive methods like polymerase chain reaction (PCR), serves as a crucial prognostic indicator in Chagas disease. Research suggests that the presence of parasitemia, identified through PCR, influences the risk of progression to chronic Chagas cardiomyopathy (CCC).^[3]This highlights its value in predicting disease outcomes and understanding the long-term implications for patients, especially those in the indeterminate stage who may appear asymptomatic but harbor the parasite. Monitoring parasitemia levels can thus help clinicians anticipate disease progression and potentially guide early intervention strategies to mitigate severe cardiac complications.

Diagnostic and Monitoring Applications

The detection of Trypanosoma cruziDNA via sensitive PCR assays is a vital clinical application for assessing active infection and parasitemia. This diagnostic utility extends beyond initial diagnosis, playing a role in risk assessment for seropositive individuals.^[1]Furthermore, parasitemia is valuable for monitoring treatment response, as a reduction or clearance of detectable parasite DNA can indicate therapeutic efficacy. Such monitoring strategies are essential for personalized medicine approaches, allowing for dynamic adjustments in patient management based on their parasitic load and infection status.

Genetic Influences and Risk Factors

Genetic factors can influence an individual’s susceptibility to parasitemia and its subsequent clinical manifestations. A genome-wide association study (GWAS) identified a cluster of 12 single nucleotide polymorphisms (SNPs) within introns of theCOL14A1gene that were associated with PCR positivity, indicating a genetic predisposition to detectable parasitemia.^[2]This association suggests that genetic variations may modulate the host’s ability to control parasite replication or clearance, thereby impacting parasitemia levels and potentially contributing to the risk of developing comorbidities like Chagas cardiomyopathy. Understanding these genetic links can aid in identifying high-risk individuals and developing more targeted prevention strategies.

Epidemiological Patterns and Risk Factors

Chagas disease presents a substantial global health challenge, with an estimated 10 million individuals infected byTrypanosoma cruzi and 120 million at risk, primarily across Latin American countries.^[11]The disease’s reach has expanded due to migration from endemic regions, establishing it as a concern in non-endemic areas like the USA and Europe.^[11] The detection of T. cruziDNA through sensitive PCR assays serves as a critical indicator of parasitemia, and studies have shown that these DNA levels correlate with antibody levels in seropositive blood donors, potentially reflecting the resolution of infection over time.^[1]Beyond its role in diagnosing infection, parasitemia by PCR is also a significant prognostic factor, with research indicating its influence, alongside male sex, on the risk of progression to chronic Chagas cardiomyopathy.^[3] The observed familial aggregation of T. cruziseropositivity and the various clinical forms of Chagas disease further suggest that genetic predispositions or shared environmental factors within families contribute to disease patterns.^[12]Longitudinal studies, such as those tracking the 10-year incidence of Chagas cardiomyopathy in asymptomatic,T. cruziseropositive former blood donors, are crucial for understanding the natural history and long-term progression of the disease.^[1]

Genetic Ancestry and Population Heterogeneity

Population studies highlight the considerable genetic diversity within Chagas disease cohorts, particularly evident in highly admixed populations such as those in Brazil.^[2] For instance, a large Brazilian Chagas cohort revealed a wide range of genetic admixture, predominantly reflecting European and African ancestries, with some contributions from East Asian and Native American populations.^[2] This complex genetic landscape necessitates careful assessment and adjustment for population stratification in genetic association studies to prevent spurious findings, a process typically performed through methods like Multidimensional Scaling (MDS).^[2] Cross-population comparisons have demonstrated that genetic findings related to immune responses and Chagas pathogenesis can be inconsistent across different ethnic groups, underscoring the importance of considering ancestry-specific effects.^[7] In admixed populations, self-reported race can be a subjective cultural construct, often failing to capture the underlying genetic admixture proportions, which further emphasizes the need for objective genetic ancestry estimation in epidemiological research.^[2]

Longitudinal Cohort Investigations and Methodological Considerations

Large-scale cohort investigations are instrumental in elucidating the natural history and genetic determinants of Chagas disease and its clinical outcomes.^[2] The NHLBI Retrovirus Epidemiological Donor Study-II (REDS-II) established a retrospective cohort in Brazil, enrolling 499 T. cruziseropositive blood donors and 101 patients with clinically diagnosed Chagas cardiomyopathy.^[2] Participants in this cohort underwent extensive medical evaluations, including demographic surveys, health questionnaires, electrocardiograms, echocardiograms, and laboratory tests, providing rich phenotypic data for detailed analysis.^[2]With 580 subjects after stringent quality control, this cohort represents the largest Genome-Wide Association Study (GWAS) conducted for Chagas disease to date, offering valuable insights into temporal patterns of disease progression and genetic susceptibility.^[2] Methodological rigor is critical for the validity and generalizability of findings from such population-level studies. The genetic analysis in this cohort employed the Affymetrix Axiom Genome-Wide Latino array, specifically designed for populations with European, West African, and Native American ancestries, coupled with advanced genotype imputation techniques utilizing reference panels like the 1000 Genomes Project.^[2]While this cohort is the largest of its kind, the moderate sample size was acknowledged as a potential limitation, which may have contributed to the limited number of highly significant single nucleotide polymorphisms (SNPs) identified.^[2] To enhance statistical power and confirm suggestive findings, future research strategies include expanding existing cohorts, conducting meta-analyses, and incorporating exposed seronegative controls to investigate genetic associations with susceptibility or resistance to T. cruziinfection.^[2]

Frequently Asked Questions About Parasitemia

These questions address the most important and specific aspects of parasitemia based on current genetic research.

---

1. If I get tested, can my results change next month?

Yes, absolutely. The number of parasites in your blood can naturally go up and down over time, influenced by your immune system and the parasite’s own life cycle. Even with sensitive tests like PCR, detection can be intermittent, especially in chronic infections. So, a test result today might not be the same a few weeks later.

2. Why might my parasite test be negative, but I still feel sick?

It’s possible. Parasite levels in the blood can fluctuate, and for some infections, detection might be intermittent, meaning they’re not always present in detectable amounts when tested. The sensitivity of the specific test used can also play a role. Sometimes, even if parasites aren’t actively circulating, their effects might still cause symptoms.

3. Does my family history make me more likely to get sicker from a parasite?

Yes, it can. Your genetics, inherited from your family, play a significant role in how your body responds to infections. Specific genetic variations can influence your susceptibility to higher parasite levels or how likely you are to develop severe symptoms, such as heart complications in Chagas disease. So, a family history of severe outcomes could indicate a genetic predisposition.

4. Can I be exposed to parasites but not get very sick?

Yes, this is definitely possible. Our genes influence our immune response and how well we can control a parasitic infection. Some people have genetic factors that make them more resilient, leading to lower parasite levels or milder symptoms even after exposure, while others might be more susceptible to severe disease.

5. How do doctors know if my parasite medicine is working?

Doctors primarily monitor your parasitemia levels. If the medication is effective, they will see a reduction or even a complete clearance of parasites from your blood over time. This indicates a positive therapeutic response and helps ensure your treatment plan is successful in fighting the infection.

6. Does my diet or stress affect how many parasites I have?

While not directly detailed, complex infections and parasite levels are often influenced by many environmental factors and how they interact with your genes. Things like your overall health, immune status (which can be affected by diet and stress), and other lifestyle factors can contribute to the dynamics of parasitemia. These non-genetic factors are important for understanding the full picture.

7. Why did I get really sick, but my friend didn’t?

This often comes down to individual differences, especially in your genetic makeup. Host genetic factors can significantly influence how your body responds to a parasitic infection, affecting both the number of parasites in your blood and your risk of developing severe disease manifestations. Your friend might have different genetic variants that offer better protection or lead to milder symptoms.

8. Is a DNA test useful to know my risk for severe parasite disease?

Potentially, yes. Research is actively identifying specific genetic variants associated with higher parasite levels or increased risk of severe disease progression, like chronic Chagas cardiomyopathy. Knowing your genetic profile could eventually help assess your personal risk and guide more targeted preventive or therapeutic strategies.

9. Does my family’s background affect how severe a parasite infection might be?

Yes, your ancestral background can certainly play a role. Populations from different regions have unique genetic histories, and these genetic differences can influence susceptibility to infections and the severity of disease. For instance, studies show that genetic findings in one population might not directly apply to others due to varying genetic compositions.

10. Could my parasite levels go up and down without me knowing?

Yes, absolutely. Parasite levels in your blood can fluctuate significantly throughout an infection, sometimes without noticeable symptoms or outward signs. This intermittent presence means you could have varying parasite loads that are only detectable through specific tests, making regular monitoring crucial in some cases.

---

This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.

Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.

References

[1] Sabino, E. C., et al. “Antibody levels correlate with detection of Trypanosoma cruzi DNA by sensitive PCR assays in seropositive blood donors and possible resolution of infection over tim.”Transfusion, vol. 53, no. 6, 2013, pp. 1257–65.

[2] Deng, Xutao, et al. “Genome Wide Association Study (GWAS) of Chagas Cardiomyopathy in Trypanosoma cruzi Seropositive Subjects.”PLoS One, vol. 8, no. 11, 2013, e79629.

[3] Basquiera, A. L., et al. “Risk progression to chronic Chagas cardiomyopathy: influence of male sex and of parasitaemia detected by polymerase chain reaction.”Heart, vol. 89, no. 10, 2003, pp. 1186–90.

[4] Lins, T. C., et al. “Genetic heterogeneity of self-reported ancestry groups in an admixed Brazilian population.” J Epidemiol, vol. 21, no. 4, 2011, pp. 240-5.

[5] Ribeiro, A. L., et al. “Diagnosis and management of Chagas disease and cardiomyopathy.”Nat Rev Cardiol, vol. 9, no. 10, 2012, p. 576.

[6] Cunha-Neto, E., et al. “Immunological and non-immunological effects of cytokines and chemokines in the pathogenesis of chronic Chagas disease cardiomyopathy.”Mem Inst Oswaldo Cruz, vol. 104, suppl. 1, 2009, pp. 252–8.

[7] Cunha-Neto, E., et al. “Autoimmunity.” Adv Parasitol, vol. 76, 2011, pp. 129–52.

[8] Williams-Blangero, Sarah, et al. “Genetic epidemiology of Chagas disease.”Adv Parasitol, vol. 75, 2011, pp. 147–67.

[9] Ramasawmy, R., et al. “Heterozygosity for the S180L variant of MAL/TIRAP, a gene expressing an adaptor protein in the Toll-like receptor pathway, is associated with lower risk of developing chronic Chagas cardiomyopathy.”J Infect Dis, vol. 199, no. 12, 2009, pp. 1838–45.

[10] Cunha-Neto, Edecio, et al. “TNF gene polymorphisms are associated with reduced survival in severe Chagas’ disease cardiomyopathy patients.”Microbes Infect, vol. 8, no. 3, 2006, pp. 598–603.

[11] Schofield, C. J., et al. “The future of Chagas disease control.”Trends Parasitol, vol. 22, no. 12, 2006, pp. 583–8.

[12] Silva-Grecco, R. L., et al. “Familial analysis of seropositivity to Trypanosoma cruzi and of clinical forms of Chagas disease.”Am J Trop Med Hyg, vol. 82, no. 1, 2010, pp. 45–8.